TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01625702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellSearch® CTC kit
Description: Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellSearch® CTC kit
Description: Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study: NCT05283668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: * Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~* The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser
Description: Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization.
Study: NCT02146898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Position

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Position
Study: NCT02066948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: meal pattern
Description: skew or even

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: meal pattern
Description: skew or even

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: even
Description: even amount of protein distributed between each meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: skew
Description: a skewed amount of protein is distributed between each meal
Study: NCT02146898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Position
Study: NCT04913402

Intervention type: OTHER
Intervention: Sufentanil administered by paramedics after the phone call consultation of medical doctor.
Description: Administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
Study: NCT02817776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL SMARTTOUCH® SF catheter
Description: Radiofrequency Ablation
Study: NCT04913402

Intervention type: OTHER
Intervention: Sufentanil administered by paramedics based on their competency, without consultation of medical doctor.
Description: Administration of sufentanil to patients with acute injury by paramedics with competency to administer sufentanil without medical doctor consultation.
Study: NCT02982876

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Flexible Bronchoscopy
Description: The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuvers will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle
Study: NCT00709176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief FOCUS Program
Description: Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extensive FOCUS Program
Description: Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
Study: NCT01895400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renexin (cilostazol 100mg + gingko biloba extract 80 mg)
Description: Take Renexin 1T bid po medication for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take placebo drug 1T bid po medication for 8 weeks
Study: NCT04435301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-Stimulator, NeuroConn, Germany
Description: Neurostimulation device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-Stimulator, NeuroConn, Germany
Description: Neurostimulation device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC-Stimulator, NeuroConn, Germany
Description: Neurostimulation device
Study: NCT01903772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Study: NCT02982876

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid Bronchoscopy
Description: Under general anesthesia, a rigid bronchoscope (Bryan-Dumon Series II; Bryan Corporation; Woburn, MA) will be introduced, and respiration will be maintained through jet ventilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent placement
Description: Silicone Y stent or uncovered self-expanding metallic stent will be placed in the standard fashion and good fit will be confirmed visually.
Study: NCT00023764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT03550898

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dynamic Ultrasonography
Description: Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
Study: NCT01464099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
Study: NCT01903772

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training
Study: NCT02759601

Intervention type: DRUG
Group type: OTHER
Intervention: Tefinostat
Description: Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
Study: NCT04800549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Mucositis
Description: The data of the study were obtained by conducting six interviews with each child and the family. The first interview was conducted before starting to treatment on the first day of the treatment, the second interview was conducted on the 2nd day after the treatment and the following interviews were conducted on the 4th, 8th, 16th, and 21st days and in-mouth mucosa of the patient was evaluated by taking in-mouth pictures following interviewing with the child and the family. Oral care application was conducted four times a day with sodium bicarbonate solution and a lollipop made with black mulberry syrup (after meals and before going to the bed at night). Oral care was first conducted by the researcher, the oral care was then taught to the patient and patient's relatives and the application was evaluated. Figure 1 shows the study design.
Study: NCT02951975

Intervention type: DRUG
Intervention: dexamethasone intravitreal implant
Description: Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
Study: NCT02201212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT00400816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\]
Study: NCT02475330

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
Study: NCT01410643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Macronutrient Modification
Description: reduced carbohydrate versus standard carbohydrate diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Macronutrient Modification
Description: reduced carbohydrate versus standard carbohydrate diet
Study: NCT02091466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pre-warming
Description: warming patients 30 minutes prior to anesthesia
Study: NCT02181790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser
Description: twice weekly treatments with the excimer laser for a total of 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser
Description: twice weekly treatments with the excimer laser for a total of 8 weeks.
Study: NCT03166462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation by Sleep Medicine Specialists
Description: Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
Study: NCT02181790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: 17.5mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: 17.5mg/d
Study: NCT01747343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Underwear/Differential Reinforcement
Description: Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
Study: NCT03005561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Back Sessions
Description: 100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool.
Study: NCT03813524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovalve Transfemoral Mitral Valve
Description: The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
Study: NCT01263132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F0434
Description: F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
Study: NCT05768282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30mg/day) for 28 days
Description: Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
Study: NCT04241640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam 20 MG/ML
Description: Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03884413

Intervention type: OTHER
Intervention: questionnaires
Description: Longitudinal observational study. Collection of health data using self-administered questionnaires online.

Intervention type: OTHER
Intervention: questionnaires
Description: Longitudinal observational study. Collection of health data using self-administered questionnaires online.
Study: NCT03474939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Oral Tablet
Description: Midazolam Oral tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Glucose 1000mg tablet night before surgery and 60 minutes before surgery
Study: NCT01246024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERG
Description: scotopic and photopic ERG
Study: NCT05072834

Intervention type: PROCEDURE
Intervention: Upper Gastrointestinal Endoscopy
Description: Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken.

Intervention type: PROCEDURE
Intervention: Upper Gastrointestinal Endoscopy
Description: Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken.
Study: NCT03399331

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manuka honey
Description: 5 for children or 10cc of honey for adults was ordered directly from a New Zealand company

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil
Description: 5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
Study: NCT02704403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01731756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leaf extract of A. indica
Description: Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
Study: NCT04808336

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection.
Description: Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation surgical procedure
Description: Group 2: thirty patients underwent surgery
Study: NCT01194986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]AZ12807110
Description: Radioligand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]AZ12807110
Description: Radioligand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Study: NCT01731756

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salicylic Acid (6%)
Description: Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salicylic Acid (6%)
Description: Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum jelly
Description: Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Petroleum jelly
Description: Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
Study: NCT00813774

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab pegol
Description: Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: 200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
Study: NCT04547127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent anti-SARS-CoV-2 MBT Plasma
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: SMT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: SMT
Study: NCT02796079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline injections
Study: NCT01160042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin Tablets 1000 mg
Study: NCT01464099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
Study: NCT03863249

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCALE AND ROOT PLANING
Description: SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCALE AND ROOT PLANING
Description: SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA).
Study: NCT01329783

Intervention type: OTHER
Intervention: maraviroc
Description: No intervention is distributed during this trial.
Study: NCT00509795

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.